FI3964510T3 - Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö - Google Patents
Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö Download PDFInfo
- Publication number
- FI3964510T3 FI3964510T3 FIEP20798924.5T FI20798924T FI3964510T3 FI 3964510 T3 FI3964510 T3 FI 3964510T3 FI 20798924 T FI20798924 T FI 20798924T FI 3964510 T3 FI3964510 T3 FI 3964510T3
- Authority
- FI
- Finland
- Prior art keywords
- crystal form
- pattern
- ray powder
- angles
- curve
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims 58
- 150000001875 compounds Chemical class 0.000 title claims 9
- 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 24
- 238000002411 thermogravimetry Methods 0.000 claims 18
- 238000000113 differential scanning calorimetry Methods 0.000 claims 12
- 230000004580 weight loss Effects 0.000 claims 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012065 filter cake Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364694 | 2019-04-30 | ||
| PCT/CN2020/088451 WO2020221358A1 (zh) | 2019-04-30 | 2020-04-30 | Wee1抑制剂化合物的晶型及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3964510T3 true FI3964510T3 (fi) | 2024-07-24 |
Family
ID=73029676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20798924.5T FI3964510T3 (fi) | 2019-04-30 | 2020-04-30 | Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12291536B2 (enExample) |
| EP (1) | EP3964510B1 (enExample) |
| JP (1) | JP7582970B2 (enExample) |
| CN (1) | CN113784968B (enExample) |
| AU (1) | AU2020266956B2 (enExample) |
| BR (1) | BR112021021230A8 (enExample) |
| CA (1) | CA3138240C (enExample) |
| DK (1) | DK3964510T3 (enExample) |
| ES (1) | ES2984617T3 (enExample) |
| FI (1) | FI3964510T3 (enExample) |
| HR (1) | HRP20241008T1 (enExample) |
| HU (1) | HUE068061T2 (enExample) |
| IL (1) | IL287472A (enExample) |
| LT (1) | LT3964510T (enExample) |
| PL (1) | PL3964510T3 (enExample) |
| PT (1) | PT3964510T (enExample) |
| RS (1) | RS65747B1 (enExample) |
| SG (1) | SG11202111315XA (enExample) |
| SI (1) | SI3964510T1 (enExample) |
| SM (1) | SMT202400303T1 (enExample) |
| WO (1) | WO2020221358A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| NZ598071A (en) * | 2006-10-27 | 2013-08-30 | Signal Pharm Llc | Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
| EP2155752B1 (en) * | 2007-04-25 | 2018-09-19 | Merck Sharp & Dohme Corp. | Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor |
| WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| PL2477628T3 (pl) | 2009-09-15 | 2015-02-27 | Merck Sharp & Dohme | Wytwarzanie krystalicznych hemihydratowych postaci dihydropirazolopirymidynonu |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| EP2731953A1 (en) | 2011-07-15 | 2014-05-21 | Abbvie Inc. | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| EP2776434A1 (en) | 2011-10-20 | 2014-09-17 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| MX2014010176A (es) | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| CA3003737C (en) | 2015-11-01 | 2021-09-14 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of making and using the same |
| CN108623615B (zh) | 2017-03-23 | 2022-12-13 | 上海迪诺医药科技有限公司 | 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用 |
| JP7290638B2 (ja) | 2017-11-01 | 2023-06-13 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Ｗｅｅ１阻害剤としての大環状化合物及びその使用 |
| EP3875460A4 (en) | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF |
-
2020
- 2020-04-30 PT PT207989245T patent/PT3964510T/pt unknown
- 2020-04-30 CN CN202080031816.4A patent/CN113784968B/zh active Active
- 2020-04-30 LT LTEPPCT/CN2020/088451T patent/LT3964510T/lt unknown
- 2020-04-30 RS RS20240816A patent/RS65747B1/sr unknown
- 2020-04-30 SG SG11202111315XA patent/SG11202111315XA/en unknown
- 2020-04-30 SI SI202030468T patent/SI3964510T1/sl unknown
- 2020-04-30 FI FIEP20798924.5T patent/FI3964510T3/fi active
- 2020-04-30 US US17/607,447 patent/US12291536B2/en active Active
- 2020-04-30 JP JP2021564588A patent/JP7582970B2/ja active Active
- 2020-04-30 ES ES20798924T patent/ES2984617T3/es active Active
- 2020-04-30 DK DK20798924.5T patent/DK3964510T3/da active
- 2020-04-30 BR BR112021021230A patent/BR112021021230A8/pt unknown
- 2020-04-30 HU HUE20798924A patent/HUE068061T2/hu unknown
- 2020-04-30 HR HRP20241008TT patent/HRP20241008T1/hr unknown
- 2020-04-30 AU AU2020266956A patent/AU2020266956B2/en active Active
- 2020-04-30 PL PL20798924.5T patent/PL3964510T3/pl unknown
- 2020-04-30 SM SM20240303T patent/SMT202400303T1/it unknown
- 2020-04-30 CA CA3138240A patent/CA3138240C/en active Active
- 2020-04-30 WO PCT/CN2020/088451 patent/WO2020221358A1/zh not_active Ceased
- 2020-04-30 EP EP20798924.5A patent/EP3964510B1/en active Active
-
2021
- 2021-10-21 IL IL287472A patent/IL287472A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12291536B2 (en) | 2025-05-06 |
| PL3964510T3 (pl) | 2024-08-19 |
| CA3138240A1 (en) | 2020-11-05 |
| AU2020266956A1 (en) | 2021-10-28 |
| JP2022530812A (ja) | 2022-07-01 |
| HUE068061T2 (hu) | 2024-12-28 |
| PT3964510T (pt) | 2024-07-29 |
| DK3964510T3 (da) | 2024-07-29 |
| ES2984617T3 (es) | 2024-10-30 |
| BR112021021230A8 (pt) | 2023-04-25 |
| EP3964510A4 (en) | 2023-04-26 |
| SG11202111315XA (en) | 2021-11-29 |
| IL287472A (en) | 2021-12-01 |
| LT3964510T (lt) | 2024-08-12 |
| SMT202400303T1 (it) | 2024-09-16 |
| HRP20241008T1 (hr) | 2024-11-08 |
| RS65747B1 (sr) | 2024-08-30 |
| JP7582970B2 (ja) | 2024-11-13 |
| BR112021021230A2 (enExample) | 2021-12-21 |
| EP3964510A1 (en) | 2022-03-09 |
| US20220220120A1 (en) | 2022-07-14 |
| EP3964510B1 (en) | 2024-07-03 |
| CN113784968A (zh) | 2021-12-10 |
| SI3964510T1 (sl) | 2024-10-30 |
| CA3138240C (en) | 2025-04-01 |
| WO2020221358A1 (zh) | 2020-11-05 |
| CN113784968B (zh) | 2024-03-15 |
| AU2020266956B2 (en) | 2025-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3964510T3 (fi) | Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö | |
| JP2021530565A5 (enExample) | ||
| JPS5940829B2 (ja) | メルカプトエチル置換グアニジンの製法 | |
| JP2008507566A5 (enExample) | ||
| JP2015063536A5 (enExample) | ||
| JP2019504103A5 (enExample) | ||
| CN109485614A (zh) | 三环的合成嗪工艺 | |
| CN102639522A (zh) | 3-(4-氨基-1-氧代-1, 3-二氢-异吲哚-2-基)-哌啶-2, 6-二酮的固体形式及制备它们的方法 | |
| CN111278820A (zh) | 一种吡啶酮化合物的晶型、盐型及其制备方法 | |
| JP2018522945A5 (enExample) | ||
| WO2014054955A4 (en) | A method for preparing microporous mof materials | |
| CN106604916A (zh) | 钾离子竞争性酸阻滞剂的晶型及其制备方法 | |
| RU2020114890A (ru) | Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина | |
| JP6820201B2 (ja) | Ｎ−メチルピペラジンジフェノールアミド及び関連組成物の合成方法 | |
| JP7343526B2 (ja) | セルデュラチニブの合成 | |
| JP2017511361A5 (enExample) | ||
| CN114746431A (zh) | 一种lrrk2抑制剂的晶型及其制备方法 | |
| JP6474430B2 (ja) | Ｐｄｅ１０阻害剤の調製のための方法および中間体 | |
| CN103408507A (zh) | 一种2-氨基-1,3,4 噻二唑类化合物的制备方法 | |
| CN111417633A (zh) | 一种β-内酰胺酶抑制剂的晶型及其制备方法 | |
| RU2021134141A (ru) | Кристаллическая форма ингибирующего wee1 соединения и ее применение | |
| CN111356676A (zh) | 作为ppar激动剂的吡咯烷衍生物的无定形及其制备方法 | |
| CN103113205A (zh) | 一种乙酰丙酮铁的制备方法 | |
| CN105367514B (zh) | 一种以吩噻嗪为原料合成2‑乙酰吩噻嗪的方法 | |
| CN116655528B (zh) | 一种氯化1-甲基烟酰铵的制备方法 |